H19, A SURFACE-MEMBRANE MOLECULE INVOLVED IN T-CELL ACTIVATION, INHIBITS CHANNEL FORMATION BY HUMAN-COMPLEMENT

被引:45
作者
WHITLOW, MB
IIDA, K
STEFANOVA, I
BERNARD, A
NUSSENZWEIG, V
机构
[1] NYU, SCH MED, KAPLAN CANC CTR, NEW YORK, NY 10003 USA
[2] CZECHOSLOVAK ACAD SCI, INST MOLEC GENET, CS-14220 PRAGUE 4, CZECHOSLOVAKIA
[3] NYU, SCH MED, DEPT PATHOL, NEW YORK, NY 10003 USA
[4] INST GUSTAVE ROUSSY, IMMUNOL TUMEURS ENFANT LAB, F-94805 VILLEJUIF, FRANCE
关键词
D O I
10.1016/0008-8749(90)90310-N
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Here we compare the properties of leukocyte antigens H19 and CD59 with those of the PI-linked 18,000-20,000 Mr molecules which inhibit lysis of human cells by the autologous terminal complement components C5b-9. H19, a 19,000 Mr protein found on human erythrocytes, monocytes, neutrophils, T-lymphocytes and other cells, is one of the ligands involved in the spontaneous rosette formation between human T-lymphocytes and erythrocytes. Recent evidence indicates that H19 also participates in T-cell activation. CD59 is a widely distributed 18,000-25,000 Mr protein anchored to the cell membrane by phosphatidylinositol (PI). The function of CD59 is unknown. Affinity-purified H19 incorporates into cell membranes and inhibits channel formation by human C5b-9 on guinea pig erythrocytes. Significant inhibition is achieved with picogram quantities of H19, corresponding to approximately 600 molecules per erythrocyte. H19 is most effective when C9 is limiting but quite active when C5b-7 or C8 are limiting, indicating that it may interact with several of the structurally related terminal complement components. The inhibitory activity is blocked by mAbs to either CD59 or to H19. H19 is PI-anchored: it is released from the cell membrane by treatment with PI-specific phospholipase C, and it is absent from cells from a patient with paroxysmal nocturnal hemoglobinuria (PNH). Analysis of PNH erythrocytes after treatment with terminal complement proteins shows that the H19-negative erythrocytes are more susceptible to C5b-9-mediated lysis. Treatment of normal human erythrocytes with either anti-H19 or anti-CD59 renders them more susceptible to lysis by human C5b-9. We conclude that H19 and CD59 are probably the same molecule and are identical or closely related to the recently described inhibitors of C5b-9 channel formation. © 1990.
引用
收藏
页码:176 / 184
页数:9
相关论文
共 29 条
[1]   STRUCTURAL HOMOLOGY OF COMPLEMENT PROTEIN-C6 WITH OTHER CHANNEL-FORMING PROTEINS OF COMPLEMENT [J].
CHAKRAVARTI, DN ;
CHAKRAVARTI, B ;
PARRA, CA ;
MULLEREBERHARD, HJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (08) :2799-2803
[2]   CD59, AN LY-6-LIKE PROTEIN EXPRESSED IN HUMAN LYMPHOID-CELLS, REGULATES THE ACTION OF THE COMPLEMENT MEMBRANE ATTACK COMPLEX ON HOMOLOGOUS CELLS [J].
DAVIES, A ;
SIMMONS, DL ;
HALE, G ;
HARRISON, RA ;
TIGHE, H ;
LACHMANN, PJ ;
WALDMANN, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (03) :637-654
[3]  
GROUX H, 1989, J IMMUNOL, V142, P3013
[4]   MECHANISM OF LYMPHOCYTE-MEDIATED CYTO-TOXICITY [J].
HENKART, PA .
ANNUAL REVIEW OF IMMUNOLOGY, 1985, 3 :31-58
[5]   SEQUENCE OF THE BACILLUS-THURINGIENSIS PHOSPHATIDYLINOSITOL SPECIFIC PHOSPHOLIPASE-C [J].
HENNER, DJ ;
YANG, M ;
CHEN, E ;
HELLMISS, R ;
RODRIGUEZ, H ;
LOW, MG .
NUCLEIC ACIDS RESEARCH, 1988, 16 (21) :10383-10383
[6]   ISOLATION AND CHARACTERIZATION OF A MEMBRANE-PROTEIN FROM NORMAL HUMAN-ERYTHROCYTES THAT INHIBITS REACTIVE LYSIS OF THE ERYTHROCYTES OF PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA [J].
HOLGUIN, MH ;
FREDRICK, LR ;
BERNSHAW, NJ ;
WILCOX, LA ;
PARKER, CJ .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (01) :7-17
[7]  
HOLLANDER N, 1989, J IMMUNOL, V142, P3913
[8]   RESISTANCE OF CYTOLYTIC LYMPHOCYTES TO PERFORIN-MEDIATED KILLING - LACK OF CORRELATION WITH COMPLEMENT-ASSOCIATED HOMOLOGOUS SPECIES RESTRICTION [J].
JIANG, S ;
PERSECHINI, PM ;
ZYCHLINSKY, A ;
LIU, CC ;
PERUSSIA, B ;
YOUNG, JDE .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 168 (06) :2207-2219
[9]  
JIANG SB, 1989, J IMMUNOL, V143, P1453
[10]   DISTRIBUTION OF DECAY-ACCELERATING FACTOR IN THE PERIPHERAL-BLOOD OF NORMAL INDIVIDUALS AND PATIENTS WITH PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA [J].
KINOSHITA, T ;
MEDOF, ME ;
SILBER, R ;
NUSSENZWEIG, V .
JOURNAL OF EXPERIMENTAL MEDICINE, 1985, 162 (01) :75-92